TCGA-90-6837-01A-11R-1949-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 64
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- COAGULATION+0.440
- TNFA_SIGNALING_VIA_NFKB+0.380
- ANGIOGENESIS+0.370
- IL6_JAK_STAT3_SIGNALING+0.370
- HYPOXIA+0.360
- INFLAMMATORY_RESPONSE+0.350
- MYOGENESIS+0.300
- APICAL_JUNCTION+0.290
- KRAS_SIGNALING_UP+0.290
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.480
- OXIDATIVE_PHOSPHORYLATION-0.420
- DNA_REPAIR-0.380
- MYC_TARGETS_V1-0.380
- FATTY_ACID_METABOLISM-0.300
- MYC_TARGETS_V2-0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.250
- INTERFERON_GAMMA_RESPONSE-0.220
- ADIPOGENESIS-0.210
- PEROXISOME-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | e074ff82-1def-4bfc-8293-6b69f8984046 | — | — | 0.859 |
| 2 | TCGA-AC-A23G-01A-11R-A213-07 | — | A | 0.825 |
| 3 | a8877d9c-7dfb-4544-bbb9-7ef4176f3429 | — | — | 0.821 |
| 4 | MNG115 | — | — | 0.818 |
| 5 | SRR1516079 | — | — | 0.817 |
| 6 | TCGA-EW-A6SC-01A-12R-A32P-07 | — | A | 0.812 |
| 7 | SRR8752371 | — | — | 0.809 |
| 8 | TCGA-MP-A4TK-01A-11R-A24X-07 | — | cohortA1 | 0.807 |
| 9 | TCGA-CR-6474-01A-11R-1873-07 | — | — | 0.803 |
| 10 | 69842b4c-448a-4275-8250-7b31948c56ec | — | — | 0.803 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| COAGULATION | 0.440 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| HYPOXIA | 0.360 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.220 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |